Evidence map›Paper›PMID 36875112›Full record

ArticleFrontiers in immunology2023

Immunological priming of mesenchymal stromal/stem cells and their extracellular vesicles augments their therapeutic benefits in experimental graft-versus-host disease

Alexander Hackel, Sebastian Vollmer, Kirsten Bruderek, Stephan Lang, Sven Brandau

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. The rise of exosome-mediated mechanisms in MSC therapy.Journal of translational medicine · 2025
    Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Alexander HackelDepartment of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Sebastian VollmerDepartment of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Kirsten BruderekDepartment of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Stephan LangDepartment of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Sven BrandauDepartment of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
University of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stromal cells (MSCs) and their extracellular vesicles (EVs) exert profound anti-inflammatory and regenerative effects in inflammation and tissue damage, which makes them an attractive tool for cellular therapies. In this study we have assessed the inducible immunoregulatory properties of MSCs and their EVs upon stimulation with different combinations of cytokines. First, we found that MSCs primed with IFN-γ, TNF-α and IL-1β, upregulate the expression of PD-1 ligands, as crucial mediators of their immunomodulatory activity. Further, primed MSCs and MSC-EVs, compared to unstimulated MSCs and MSC-EVs, had increased immunosuppressive effects on activated T cells and mediated an enhanced induction of regulatory T cells, in a PD-1 dependent manner. Importantly, EVs derived from primed MSCs reduced the clinical score and prolonged the survival of mice in a model of graft-versus-host disease. These effects could be reversed

Indexed as

Extracellular VesiclesGraft vs Host DiseaseMesenchymal Stem CellsAnimalsAntibodies, NeutralizingLigandsMiceProgrammed Cell Death 1 ReceptorAntibodies, NeutralizingLigandsProgrammed Cell Death 1 Receptorcytokine primingextracellular vesicles (EVs)graft-versus-host disease (GVHD)immunomodulationmesenchymal stromal/stem cells (MSCs)programmed death ligand system (PD-1 and PD-L1)regulatory T cells (Tregs)

Identifiers

PMID36875112
PMCPMC9978482
OpenAlexW4321110299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.